Monopar Therapeutics (MNPR) Research & Development (2017 - 2020)
Monopar Therapeutics (MNPR) has disclosed Research & Development for 4 consecutive years, with $1.6 million as the latest value for Q4 2020.
- Quarterly Research & Development rose 179.62% to $1.6 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2020, up 106.51% year-over-year, with the annual reading at $4.0 million for FY2024, N/A changed from the prior year.
- Research & Development hit $1.6 million in Q4 2020 for Monopar Therapeutics, up from $1.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $1.6 million in Q4 2020 to a low of $133736.0 in Q1 2017.
- Historically, Research & Development has averaged $534657.9 across 4 years, with a median of $336850.5 in 2019.
- Biggest YoY gain for Research & Development was 471.27% in 2020; the steepest drop was 58.78% in 2020.
- Year by year, Research & Development stood at $309315.0 in 2017, then skyrocketed by 68.43% to $520982.0 in 2018, then increased by 12.05% to $583778.0 in 2019, then surged by 179.62% to $1.6 million in 2020.
- Business Quant data shows Research & Development for MNPR at $1.6 million in Q4 2020, $1.3 million in Q3 2020, and $832503.0 in Q2 2020.